17 / 23
Avelumab: PFS and OS > 1 year FUP, Part A, 2L
mPFS 2-3m of CT reported in retrospective observational
analyses
Kaufman HL, et al. Lancet Oncol. 2016, 17(10):1374-85; Kaufman. AACR 2017; Cowey et al. Future Oncol. 2017, 13(19): 1699-1710; Becker et al. Oncotarget 2017, 8(45):79731-41;
Iyer et al. Cancer Med 2016, 5:2294-2301
mOS 5.7m of CT reported in retrospective analysis
(Iyer 2016)